CD19 and acute lymphoblastic leukemia: To understand why only 26% of CLL patients benefited from CD19 CAR-T therapy while more than 90% of CD19+ B-ALL patients experienced CR, a detailed transcriptomic analysis was performed to compare CLL responses after CD19 CAR-T therapy using CAR-T cells from responders and non-responders.